Novartis AG, the multinational pharmaceutical company, has announced the recall of 183 lots of cough syrups. As per a recent report, the company has discovered that some bottle caps' child-resistant feature has not been functioning.

A new report has claimed that European approval has been successfully grabbed by Novartis for the first vaccine developed to fight meningitis B. Only this type of the illness i. e. Meningitis B has until now been lacking an effective medication against it.

Surely, it was a good news for Novartis that it has been able to have positive result of its phase III clinical study of immune system drug known as Certican. The news was worth getting happy, as it has been found that the Swiss pharmaceutical company was trying to get everything right for last two years.

Novartis AG had carried out a late-stage trial on a drug developed by it to treat acute heart failure. And as per revelations of a new report, the trial has led the company to announce partial success with failure on some grounds.

It has been reported that Novartis flu vaccine has been recalled by the German authorities due to fear of contamination. During the recall, it was informed that the Novartis flu vaccine might be containing unidentified small particles.

On Monday, the drug maker Novartis announced that its drug to treat chronic obstructive pulmonary disease has been approved in the European countries. During clinical trials it has been found that the drug is capable of treating the chronic obstructive pulmonary disease or smoker’s cough within four hours of administering.

Recently, a drug has been introduced to treat lung infection linked to cystic fibrosis. This is a newer form of Novartis AG, an inhaled antibiotic drug, and has been supported by the drug advisers on Wednesday.

It has been recently revealed that some local health authorities in the south of England are using economic eye drop, known as Avastin, for the wet age-related macular degeneration (AMD) problem. The drug is in fact not licensed for eye use, and has raised concerns among the authorities concerned.

After three clinical trials, Novartis is positive about the lung drug to hit the market soon. The drug has been designed for patients suffering from chronic obstructive pulmonary disease (COPD), often known as smokers' cough.

After coming across few death cases due to Novartis AG's multiple-sclerosis drug Gilenya, the European Medical Agency (EMA) has started an investigation which would see its pros and cons. The EMA said that the main reason to conduct the review is to make sure that the drug is safe.